ALX Oncology Holdings Inc to Discuss New Data from ASPEN-01 and the Phase 1b Study of ALX148 Call Transcript
Good morning, and welcome to the ALX Oncology Conference Call. Today's call is being recorded.
Hello, and thank you all for dialing in to today's conference call. I'm Pete Garcia, Chief Financial Officer of ALX Oncology.
Today's call will focus on the clinical data of ALX148, a CD47 myeloid checkpoint inhibitor and specifically our Phase Ib study in gastric cancer combining ALX148 with trastuzumab, ramucirumab and paclitaxel that was presented at the recently completed European Society of Medical Oncology World Congress on Gastrointestinal Cancer, also known as ESMO GI.
A slide deck for this webcast is available on our website in the Investors Events section. Dr. Jaume Pons, our President and CEO, will provide a brief overview of ALX148; and Dr. Sophia Randolph, our Chief Medical Officer, will then discuss the updated Phase Ib gastric cancer combination study. At the end of our prepared remarks, we will open the line up for questions.
Before we begin, as reflected in Slide #2, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |